Kepler Capital analyst Christian Faitz maintained a Buy rating on Carbios SA (COOSF – Research Report) on November 25 and
Tag: COOSF
Kepler Capital Believes Carbios SA (Other OTC: COOSF) Won’t Stop Here
In a report issued on November 19, Baptiste de Leudeville from Kepler Capital maintained a Buy rating on Carbios SA
Analysts Have Conflicting Sentiments on These Healthcare Companies: Carbios SA (Other OTC: COOSF) and Innate Pharma (NASDAQ: IPHA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Carbios SA (COOSF – Research
Kepler Capital Downgrades Carbios SA (COOSF) to Hold
Carbios SA (COOSF – Research Report) received a Hold rating and a EUR22.00 price target from Kepler Capital analyst Martin
Carbios SA (COOSF) was Downgraded to a Hold Rating at Kepler Capital
Kepler Capital analyst Christian Faitz downgraded Carbios SA (COOSF – Research Report) to Hold on October 27 and set a
Kepler Capital Downgrades Carbios SA (COOSF) to Hold
Kepler Capital analyst Christian Faitz downgraded Carbios SA (COOSF – Research Report) to Hold on October 14 and set a
Carbios SA (COOSF) was Downgraded to a Hold Rating at Kepler Capital
In a report issued on September 25, Christian Faitz from Kepler Capital downgraded Carbios SA (COOSF – Research Report) to